

AD _____

Award Number: W81XWH-04-1-0514

TITLE: One-Carbon Metabolism and Breast Cancer Survival in a Population-Based Study

PRINCIPAL INVESTIGATOR: Jia Chen, Ph.D.

CONTRACTING ORGANIZATION: Mount Sinai School of Medicine
New York, NY 10029-6574

REPORT DATE: June 2007

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE (DD-MM-YYYY) 01/06/07		2. REPORT TYPE Final		3. DATES COVERED (From - To) 15 May 2004 – 14 May 2007	
4. TITLE AND SUBTITLE One-Carbon Metabolism and Breast Cancer Survival in a Population-Based Study				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-04-1-0514	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Jia Chen, Ph.D. E-Mail: jia.chen@mssm.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Mount Sinai School of Medicine New York, NY 10029-6574				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT: The 5-year survival rate for BC among US women has increased from 75% during 1974-76 to 85% during 1989-95. Despite such marked improvement, BC is still the leading cause of cancer mortality among women 20 – 59 years of age and the second leading cause of cancer mortality among all women. Disease-free survival after BC treatment is likely predicted by both tumor characteristics and host factors. The clinical and pathologic parameters that have been shown to influence disease prognosis include tumor size, nodal involvement, tumor state, grade, hormone receptor status, mitotic index, expression of multi-drug resistance proteins, p53 status, and HER-2/neu status. Meanwhile, only a few host factors have been identified that impact disease-free or overall survival, particularly those that a patient may engage in to modify or help clinicians to tailor effective and efficient treatment strategy. This proposed study focuses on one-carbon metabolism, a key process for DNA methylation and DNA synthesis. One-carbon metabolism is crucial of BC prognosis because it not only provides methyl group for regulating expression of genes that have prognostic values (e.g. ER, PR, BRCA1, etc.) but also is a primary target for treatment of the disease (e.g. 5-FU, methotrexate, etc.). We propose to utilize the resources of the Long Island Breast Cancer Study Project, a large population-based study consisting of ~1500 BC cases and ~1500 controls. We will examine the dietary intake of one-carbon-related micronutrients/compounds (e.g. folate, methionine, choline, B vitamins, alcohol, etc) in relation to disease-free and overall survival of BC via the mechanism of promoter hypermethylation (presumably silencing) of the ER, PR, and BRCA1 genes. We will also examine whether functional polymorphisms in one-carbon metabolism may influence survival of BC, either through modifying the efficacy of chemotherapeutic drugs or influencing methylation of prognosis-related genes. Results from this study would help clarify mechanisms of disease progression as well as contribute to the design of a more efficient (genetically tailored) treatment strategy.					
15. SUBJECT TERMS No subject terms provided					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	8	19b. TELEPHONE NUMBER (include area code)

Table of Contents

Cover.....	
SF 298.....	
Table of Contents.....	
Introduction.....	5
Body.....	5
Key Research Accomplishments.....	8
Conclusions.....	8
Reportable Outcomes.....	8
Appendices.....	

INTRODUCTION

The 5-year survival rate for BC among US women has increased from 75% during 1974-76 to 85% during 1989-95¹. Despite such marked improvement, BC is still the leading cause of cancer mortality among women 20 – 59 years of age and the second leading cause of cancer mortality among all women. Disease-free survival after BC treatment is likely predicted by both tumor characteristics and host factors. The clinical and pathologic parameters that have been shown to influence disease prognosis include tumor size, nodal involvement, tumor state, grade, hormone receptor status, mitotic index, expression of multi-drug resistance proteins, p53 status, and HER-2/neu status. Meanwhile, only a few host factors have been identified that impact disease-free or overall survival, particularly those that a patient may engage in to modify or help clinicians to tailor effective and efficient treatment strategy. This proposed study focuses on one-carbon metabolism, a key process for DNA methylation and DNA synthesis. One-carbon metabolism is crucial of BC prognosis because it not only provides methyl group for regulating expression of genes that have prognostic values (e.g. *ER*, *PR*, *BRCA1*, etc.) but also is a primary target for treatment of the disease (e.g. 5-FU, methotrexate, etc.). We propose to utilize the resources of the Long Island Breast Cancer Study Project, a large population-based study consisting of ~1500 BC cases and ~1500 controls. We will examine the dietary intake of one-carbon-related micronutrients/compounds (e.g. folate, methionine, choline, B vitamins, alcohol, etc) in relation to disease-free and overall survival of BC *via* the mechanism of promoter hypermethylation (presumably silencing) of the *ER*, *PR*, and *BRCA1* genes. We will also examine whether functional polymorphisms in one-carbon metabolism may influence survival of BC, either through modifying the efficacy of chemotherapeutic drugs or influencing methylation of prognosis-related genes. Results from this study would help clarify mechanisms of disease progression as well as contribute to the design of a more efficient (genetically tailored) treatment strategy.

BODY

Task 1. To genotype polymorphisms in one-carbon-metabolizing genes on 1087 BC cases (Months 1- 24)

Genotyping was completed as reported previously.

Task 2. Determine the promoter methylation patterns on *ER*, *PR*, and *BRCA1* genes from ~960 BC tissues (Months 1-30)

- a. DNA extraction from ~960 tumor blocks.
- b. Set up and validate methylation assay on *ER*, *PR* and *BRCA1* genes using a real-time quantitative methylation-specific PCR method.

These tasks were completed as reported previously.

c. Ascertain methylation patterns of *ER*, *PR*, and *BRCA1* from 960 tumor tissues.

By using the methylation-specific PCR (MS-PCR) assay, we determined the methylation status of three genes, *ER* α , *PR* β and *BRCA1*, for ~850 breast cancer samples. We detected 383(44.8%) promoter hypermethylation for *ER* α ; 102(11.9%) for *PR* β ; 504(59.0%) for *BRCA1*, respectively.

d. Data entry.

All genotype and gene promoter methylation status data have been entered into our database and are ready to analyze.

Task 3. Data analyses (Months 25-36)

a. Study associations of dietary methyl content and overall survival.

Some descriptive statistical analysis has been reported in previous annual report. The Kaplan-Meier method and the log-rank test were used for univariate survival analysis for dietary B vitamin intake. The Cox Proportional-Hazards regression was used to estimate hazard ratio and 95% confidence interval (95% CI) in the age-adjusted regression models for both all-cause and breast cancer-specific mortality.

The relationship between base-line dietary B vitamin intake and overall survival was summarized in **Table 1**. Intake of vitamin B1 and B3 were found to associate with overall survival in this population. Compared to the lowest intake quintile, cases in the highest or second highest intake quintile have about 50% lower risk of death, which is statistically significant. These relationships were in dose-dependent manner (p,trend = 0.01 for both vitamin B1 and B3).

Table 1 Association between B vitamin intake and overall survival

Variable	Quintiles of intake					P, trend
	Q1	Q2	Q3	Q4	Q5	
Dietary folate						
Range(µg/d)	<159	159-216	216-279	279-356	>356	
HR(95% CI)	1.00(ref)	0.97(0.62-1.50)	0.88(0.56-1.38)	0.76(0.46-1.25)	0.81(0.47-1.39)	0.28
Total folate						
Range(µg/d)	<208	208-330	330-561	561-722	>722	
HR(95% CI)	1.00(ref)	0.78(0.50-1.20)	0.70(0.44-1.13)	0.93(0.60-1.42)	0.85(0.54-1.35)	0.80
Vitamin B1						
Range(mg/d)	<0.72	0.72-0.95	0.95-1.16	1.16-1.48	>1.48	
HR(95% CI)	1.00(ref)	0.81(0.53-1.24)	0.67(0.41-1.07)	0.50(0.29-0.86)	0.52(0.28-0.98)	0.01
Vitamin B2						
Range(mg/d)	<0.95	0.95-1.30	1.30-1.62	1.62-2.12	>2.12	
HR(95% CI)	1.00(ref)	0.97(0.63-1.50)	0.68(0.40-1.13)	0.92(0.56-1.54)	0.79(0.43-1.47)	0.47
Vitamin B3						
Range(mg/d)	<9.8	9.8-12.9	12.9-15.7	15.7-19.9	>19.9	
HR(95% CI)	1.00(ref)	0.78(0.51-1.19)	0.67(0.41-1.07)	0.48(0.28-0.81)	0.82(0.28-0.98)	0.01
Vitamin B6						
Range(mg/d)	<0.84	0.84-1.15	1.15-1.42	1.42-1.84	>1.84	
HR(95% CI)	1.00(ref)	0.71(0.46-1.10)	0.63(0.39-1.03)	0.67(0.40-1.10)	0.77(0.44-1.35)	0.35

b. Study associations of one-carbon polymorphisms and overall survival.

Follow the crude analysis of one-carbon polymorphism in relation to survival, we built multivariate model and examined the association for breast cancer specific survival. Results from the multivariate model were similar to the age-adjusted model.

Variant allele of two polymorphisms, *MTHFR677* and *BHMT*, were statistically significantly associated with better survival. The *MTHFR677* T allele carriers have 31% lower risk of death than patients with the *MTHFR677* CC genotype (HR and 95% CI: 0.69(0.49-0.98)). A allele carries *BHMT* polymorphism have 30% lower risk of death than those with the *BHMT* GG genotype (HR and 95% CI: 0.70(0.50-1.00)). Two other SNPs, *MTR2756* G and *cSHMT1420* T alleles were associated with better survival with borderline significance.

Models were run using breast cancer-specific mortality as outcome (data not shown) and the results were similar to those for all-cause mortality as outcome.

In **Table 2**, results of subgroup analysis were summarized. Cases were divided into two groups: ER+PR+ cases and otherwise (ER+/PR-, ER-/PR+, ER-/PR-) due to the relative infrequency. The association of one-carbon metabolism polymorphisms and overall survival was different by ER/PR status for several polymorphisms, i.e. *MTHFR C677T* (p,int = 0.05). ER/PR status significantly modified the effect of *MTHFR677* on survival with the T allele was associated with worse survival among ER+/PR+ cases. However, the point estimate was not significant.

Table 2 Stratified analysis of associations of one-carbon polymorphisms with overall survival

Gene	Genotype	ER/PR status		Chemotherapy	
		+	-	yes	no
		HR	HR	HR	HR
<i>MTHFR</i> (<i>C677T</i>)	0	1.00(ref)	1.00(ref)	1.00(ref)	1.00(ref)
	1	1.47	0.61	1.13	0.86
	P,int	0.05		0.55	
<i>MTHFR</i> (<i>A1208C</i>)	0	1.00(ref)	1.00(ref)	1.00(ref)	1.00(ref)
	1	1.27	0.66	1.22	0.91
	P,int	0.13		0.64	
<i>TSTR</i> (<i>5'-UTR</i>)	0	1.00(ref)	1.00(ref)	1.00(ref)	1.00(ref)
	1	0.59	1.06	1.59	0.51
	P,int	0.21		0.13	
<i>DHRF</i> (<i>19bp del</i>)	0	1.00(ref)	1.00(ref)	1.00(ref)	1.00(ref)
	1	1.51	0.68	0.82	1.34
	P,int	0.10		0.61	
<i>MTR</i> (<i>A2756G</i>)	0	1.00(ref)	1.00(ref)	1.00(ref)	1.00(ref)
	1	0.66	0.84	0.83	1.33
	P,int	0.64		0.5	
<i>MTRR</i> (<i>A66G</i>)	0	1.00(ref)	1.00(ref)	1.00(ref)	1.00(ref)
	1	0.59	0.70	0.60	0.63
	P,int	0.72		1	
<i>BHMT</i> (<i>G742A</i>)	0	1.00(ref)	1.00(ref)	1.00(ref)	1.00(ref)
	1	1.21	0.61	0.62	0.66
	P,int	0.12		0.78	
<i>RFC1</i> (<i>A80G</i>)	0	1.00(ref)	1.00(ref)	1.00(ref)	1.00(ref)
	1	1.28	1.12	0.99	0.81
	P,int	0.78		0.97	
<i>cSHMT</i> (<i>C1420T</i>)	0	1.00(ref)	1.00(ref)	1.00(ref)	1.00(ref)
	1	1.20	0.58	0.79	0.77
	P,int	0.09		0.91	

c. Study associations of one-carbon metabolism (diet and polymorphism) and methylation patterns of ER, PR and BRCA1.

We explored the association of dietary and total folate intake and gene promoter methylation status. Only PR-beta methylation status was correlated with total folate intake. Compared to the lower intake group, the higher intake group has higher percentage of methylation.

In the crude analyses, polymorphisms of one-carbon metabolism pathway do not predict methylation status of these three genes. However, cases with 2R/2R genotype of the TS gene are more likely to have methylated ER α (OR:1.68; 95%CI: 1.06-2.65).

d. Study associations of methylation pattern and overall survival.

The survival does not differ by the methylation status of ER α , PR β and BRCA1. However, BRCA1 has the P value for log-rank test 0.0545 between unmethylated and methylated group, which indicates a small difference. The BRCA1 methylated cases have worse survival with a HR of 1.45(95%CI: 0.99-2.11).

e. Study survival relationship by treatment regimen (i.e. chemotherapy vs. no chemotherapy).

Cases were divided into two groups by whether received chemotherapy. This analysis was carried out to explore the potential modifying effect of one-carbon gene polymorphisms on chemotherapy response in relation to breast cancer survival. Results were summarized in **Table 2**. The association of one-carbon metabolism polymorphism and overall survival does not differ by whether received chemotherapy or not.

f. Manuscript preparation.

In progress.

KEY RESEARCH ACCOMPLISHMENTS

1. We have completed the promoter methylation status detection for three genes, namely ER α , PR β and BRCA1.
2. All data from lab measurement have been entered into our database for analysis.
3. Preliminary analysis were done for association between dietary methyl content and overall survival; one-carbon polymorphisms and overall survival; one-carbon metabolism and gene promoter methylation patterns; gene promoter methylation pattern and overall survival; and one-carbon polymorphisms and treatment regimen in relation to survival.

CONCLUSIONS

We found two one-carbon polymorphisms, namely, *MTHFR C677T* and *BHMT G742A*, were statistically significantly associate with overall survival which indicates that one-carbon may play important role in disease prognosis. Gene promoter methylation status was not found to be significant associated survival in this population.

REPORTABLE OUTCOMES

Manuscripts: These works have been supported by the award.

X Xu, MD Gammon, JG Wetmur, M Rao, MM Gaudet, SL Teitelbaum, JA Britton, AI Neugut, RM Santella, and J Chen. A functional 19-base pair deletion polymorphism of dihydrofolate reductase (DHFR) and risk of breast cancer in multivitamin users. *Am J Clin Nutr* ; 85(4): 1098-1102

Xu X, Gammon MD, Zhang H, Wetmur JG, Rao M, Teitelbaum SL, Britton JA, Neugut AI, Santella RM, Chen J. Polymorphisms of One-carbon Metabolizing Genes and Risk of Breast Cancer in a Population-based Study. *Carcinogenesis*. 2007 Mar 19; [Epub ahead of print].

APPENDICES

None

A NOTE ON IRB VIOLATION:

During the renewal process of this study, we discovered a mistake that has been made during the current funding period. During last year's renewal process, the study protocol was reclassified by my institution's IRB from "Exempt category #4" to requiring approval of a convened IRB. The application was reviewed by the Mount Sinai IRB and was conditionally approved pending receipt of my signatures on two IRB forms. The MSSM IRB posting was issued on July 20, 2006, during which time I was on a working trip in China. Unfortunately, I failed to follow-up on the MSSM IRB's request to sign the forms I submitted. Therefore the IRB never issued a formal approval for the research. While the content of my research was appropriately reviewed and found approvable by the IRB, my failure to follow up on the administrative component of my application caused the lack of issuance of a formal IRB approval. The mistake was not recognized until the time of this renewal. I, as the PI, will take full responsibility for this mistake. In the meantime, I offer my assurance that no harm has been done to human subjects because the study used existing data only; there was no patient recruitment or follow-up that occurred during the course of the study. Further, all the data on which we performed our analyses are coded; no investigator at MSSM has the linkable information to study participants. We have informed our IRB of the error and have submitted a corrective action plan to prevent this from occurring in the future, and our IRB has accepted the plan on the condition that we inform the DOD of our error.